BRPI0318278B8 - Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro - Google Patents

Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro

Info

Publication number
BRPI0318278B8
BRPI0318278B8 BRPI0318278A BR0318278A BRPI0318278B8 BR PI0318278 B8 BRPI0318278 B8 BR PI0318278B8 BR PI0318278 A BRPI0318278 A BR PI0318278A BR 0318278 A BR0318278 A BR 0318278A BR PI0318278 B8 BRPI0318278 B8 BR PI0318278B8
Authority
BR
Brazil
Prior art keywords
compounds
composition
aminocyclohexyl ether
ion channel
channel activity
Prior art date
Application number
BRPI0318278A
Other languages
English (en)
Other versions
BRPI0318278B1 (pt
BR0318278A (pt
Inventor
Alexander Zolotoy
G M Barrett Anthony
Bertrand Plouvier
Ta Hung Chou Doug
Grace Jung
N Beatch Gregory
Jeff Zhu
Siu Leung Choi Lewis
J A Walker Michael
Richard Wall
L Yong Sandro
Tao Sheng
Yuzhong Liu
Original Assignee
Cardiome Pharma Corp
Correvio Canada Corp
Correvio Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiome Pharma Corp, Correvio Canada Corp, Correvio Int Sarl filed Critical Cardiome Pharma Corp
Publication of BR0318278A publication Critical patent/BR0318278A/pt
Publication of BRPI0318278B1 publication Critical patent/BRPI0318278B1/pt
Publication of BRPI0318278B8 publication Critical patent/BRPI0318278B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

compostos de éter aminocicloexílico e usos dos mesmos. são divulgados compostos de éter aminocicloexílico. os compostos da presente invenção podem ser incorporados em composições e kits. a presente invenção também divulga os usos para os compostos e as composições, incluindo o tratamento de arritmia.
BRPI0318278A 2003-05-02 2003-10-31 Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro BRPI0318278B8 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US46715903P 2003-05-02 2003-05-02
US47608303P 2003-06-04 2003-06-04
US47588403P 2003-06-05 2003-06-05
US47644703P 2003-06-05 2003-06-05
US47591203P 2003-06-05 2003-06-05
US48965903P 2003-07-23 2003-07-23
US49339203P 2003-08-07 2003-08-07
PCT/US2003/034655 WO2004099137A1 (en) 2003-05-02 2003-10-31 Aminocyclohexyl ether compounds and uses thereof

Publications (3)

Publication Number Publication Date
BR0318278A BR0318278A (pt) 2006-05-23
BRPI0318278B1 BRPI0318278B1 (pt) 2018-11-06
BRPI0318278B8 true BRPI0318278B8 (pt) 2024-01-09

Family

ID=33437310

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018009866A BR122018009866B8 (pt) 2003-05-02 2003-10-31 métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
BRPI0318278A BRPI0318278B8 (pt) 2003-05-02 2003-10-31 Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122018009866A BR122018009866B8 (pt) 2003-05-02 2003-10-31 métodos para preparar compostos de éter aminocicloexílico e compostos intermediários

Country Status (21)

Country Link
US (3) US20070099983A1 (pt)
EP (3) EP2298735A1 (pt)
JP (2) JP4919661B2 (pt)
KR (1) KR101059379B1 (pt)
AT (2) ATE325789T1 (pt)
AU (2) AU2003287378B2 (pt)
BR (2) BR122018009866B8 (pt)
CA (1) CA2524323C (pt)
CY (1) CY1105137T1 (pt)
DE (1) DE60305200T2 (pt)
DK (1) DK1560812T3 (pt)
ES (2) ES2264776T3 (pt)
IL (2) IL171653A (pt)
NO (1) NO334094B1 (pt)
NZ (1) NZ543921A (pt)
PL (1) PL227937B1 (pt)
PT (1) PT1560812E (pt)
RU (1) RU2478617C2 (pt)
SG (2) SG167670A1 (pt)
SI (1) SI1560812T1 (pt)
WO (1) WO2004099137A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422217A3 (en) * 1998-04-01 2004-06-16 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US20080063707A1 (en) * 2003-05-02 2008-03-13 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
KR101059379B1 (ko) * 2003-05-02 2011-08-26 카디오메 파마 코포레이션 아미노사이클로헥실 에테르 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US7345086B2 (en) 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
US7674820B2 (en) 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US7977373B2 (en) 2004-04-01 2011-07-12 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
US7705036B2 (en) 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
WO2006138673A2 (en) 2005-06-15 2006-12-28 Cardiome Pharma Corp. Synthetic processes for the preparation of aminocyclohexyl ether compounds
JP4954864B2 (ja) * 2004-04-01 2012-06-20 カーディオム ファーマ コーポレイション イオンチャネル調節化合物のプロドラッグおよびその使用
US8058304B2 (en) 2004-04-01 2011-11-15 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
US8263638B2 (en) 2004-11-08 2012-09-11 Cardiome Pharma Corp. Dosing regimens for ion channel modulating compounds
JP5159314B2 (ja) * 2004-11-18 2013-03-06 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物の合成方法
CA2594680A1 (en) * 2005-01-12 2006-07-20 Astellas Pharma Inc. Production method of optically active cyclohexane ether compounds
JP4167297B2 (ja) * 2005-08-23 2008-10-15 株式会社カネカ ３−アラルキルオキシピロリジン誘導体の製造法
EP1950198B1 (en) * 2005-10-31 2014-08-06 Toray Fine Chemicals Co., Ltd. Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative
JP2007131597A (ja) * 2005-11-11 2007-05-31 Toray Fine Chemicals Co Ltd ベンジルオキシピロリジン誘導体の製造方法
JP5004073B2 (ja) * 2006-06-13 2012-08-22 東レ・ファインケミカル株式会社 光学活性ベンジルオキシピロリジン誘導体塩酸塩粉体及びその製造法
JP5004067B2 (ja) * 2005-10-31 2012-08-22 東レ・ファインケミカル株式会社 ベンジルオキシ含窒素環状化合物の製造法
JP2010526102A (ja) * 2007-05-04 2010-07-29 カーディオム ファーマ コーポレイション イオンチャネル調節化合物の制御放出経口製剤および不整脈を予防するための関連する方法
EP2605772B1 (en) 2010-08-16 2016-06-22 Cardiome International AG Process for preparing aminocyclohexyl ether compounds
US8932836B2 (en) 2010-08-16 2015-01-13 Codexis, Inc. Biocatalysts and methods for the synthesis of (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine
US10323145B2 (en) * 2014-08-01 2019-06-18 Covestro Deutschland Ag Copolycarbonate compositions with cyclic and linear oligomers and improved optical properties

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2954380A (en) * 1958-11-26 1960-09-27 Us Vitamin Pharm Corp Piperazinocyclohexyl esters
US3218328A (en) * 1963-02-18 1965-11-16 U S Vitamin & Pharmacentical C Heterocyclic amino phenoxyacetic acids, acid addition salts and quaternary ammonium salts thereof
DE2259260A1 (de) 1972-12-04 1974-06-06 Merck Patent Gmbh Neue amine
US4145435A (en) * 1976-11-12 1979-03-20 The Upjohn Company 2-aminocycloaliphatic amide compounds
US4179501A (en) * 1976-11-12 1979-12-18 The Upjohn Company Analgesic N-(2-aminocycloaliphatic)azidobenzamides
DE2658401A1 (de) 1976-12-23 1978-07-06 Merck Patent Gmbh Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4598087A (en) 1983-12-06 1986-07-01 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US4656182A (en) 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
GB2159816B (en) * 1984-05-18 1989-05-24 Glaxo Group Ltd Aminocyclopentyl ethers and their preparation and pharmaceutical formulation
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
DE3668268D1 (de) 1985-10-25 1990-02-22 Upjohn Co Verwendung von cis-n-(2-aminocycloaliphatische) benzen acetamid und benzamid zur herstellung von antikrampfmittel.
US5059620A (en) * 1985-12-27 1991-10-22 The Du Pont Merck Pharmaceutical Company Aryl substituted aminomethyl benzene derivatives
US4855316A (en) * 1988-02-18 1989-08-08 Warner-Lambert Company 1,2-diamino-4,5-dimethoxycyclohexyl amide analgesic compounds
US5051428A (en) * 1988-12-06 1991-09-24 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
AU626949B2 (en) 1988-12-06 1992-08-13 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
US4906655A (en) * 1989-01-24 1990-03-06 Warner-Lambert Company Novel 1,2-cyclohexylaminoaryl amides useful as analgesic agents
JPH02270864A (ja) 1989-04-12 1990-11-05 Asahi Glass Co Ltd フルオロカルバサイクリックヌクレオシドおよびその製造法
US5428031A (en) * 1991-12-03 1995-06-27 Merck & Co., Inc. Methods of treating cardiac arrhythmia
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
CA2058502A1 (en) 1991-12-27 1993-06-28 David C. Horwell 2-amino-mono-methoxycyclohexyl amides useful as analgesics
EP0552386A1 (en) 1992-01-13 1993-07-28 Warner-Lambert Company 2-Amino-3 or 6-methoxycyclohexyl amide derivatives
US5506257A (en) * 1992-03-26 1996-04-09 University Of British Columbia Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
DE69311896T2 (de) 1992-03-26 1997-10-16 University Of British Columbia, Vancouver, British Columbia Aminocyclohexylamide für antiarrhythmische und anästhetische verwendungen
GB9220286D0 (en) 1992-09-25 1992-11-11 Merck Sharp & Dohme Therapeutic agents
US5451596A (en) 1992-12-29 1995-09-19 Rhone Poulenc Rorer Pharmaceuticals Inc. Cycloalkyl amine bis-aryl squalene synthase inhibitors
US5747278A (en) * 1993-05-21 1998-05-05 California Institute Of Technology DNA encoding inward rectifier, G-protein activated, mammalian, potassium KGA channel and uses thereof
US5492825A (en) * 1993-08-06 1996-02-20 The Regents Of The University Of California Mammalian inward rectifier potassium channel cDNA, IRK1, corresponding vectors, and transformed cells
CA2172513C (en) * 1993-09-24 2008-01-08 Bernard A. Macleod Aminocyclohexylesters and uses thereof
GB9406043D0 (en) * 1994-03-26 1994-05-18 Smithkline Beecham Plc Compounds
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
JPH10503768A (ja) * 1994-08-02 1998-04-07 メルク シヤープ エンド ドーム リミテツド アゼチジン、ピロリジンおよびピペリジン誘導体
ATE212860T1 (de) * 1994-09-19 2002-02-15 Fujisawa Pharmaceutical Co Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
US5556990A (en) 1994-12-16 1996-09-17 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polyarylcarbamoylaza- and -carbamoylalkanedioic acids
JP3789938B2 (ja) 1995-02-03 2006-06-28 ビーエーエスエフ アクチェンゲゼルシャフト 酵素触媒作用アシル化による１級及び２級のヘテロ原子置換アミンのラセミ体分割
PL328199A1 (en) 1996-01-25 1999-01-18 Schering Ag Improved concentrated intravascular injection and infusion solutions
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5646151A (en) 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
PL330850A1 (en) 1996-06-27 1999-06-07 Smithkline Beecham Corp Antagonists of il-8 receptors
US5935945A (en) * 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US6180632B1 (en) * 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
TW536401B (en) 1997-09-03 2003-06-11 Cardiome Pharma Corp A pharmaceutical composition of N,N-bis(phenylcarbamoylmethyl)dimethylammomum chloride and derivatives for the treatment of pain
AU9248698A (en) 1997-09-26 1999-04-23 Nortran Pharmaceuticals Inc. Mixtures of enantiomers of aminocyclohexylamides to produce simultaneous analgesia with local anaesthesia or antiarrhythmia
JP3773644B2 (ja) * 1998-01-06 2006-05-10 芝府エンジニアリング株式会社 接点材料
US6013830A (en) 1998-03-30 2000-01-11 Sepracor Inc. Asymmetric grignard synthesis with cyclic 1,2 aminoalcohols
EP1422217A3 (en) * 1998-04-01 2004-06-16 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US6624761B2 (en) * 1998-12-11 2003-09-23 Realtime Data, Llc Content independent data compression method and system
US6979685B1 (en) * 1999-02-12 2005-12-27 Cardiome Pharma Corp. Cycloalkyl amine compounds and uses thereof
AU2528900A (en) 1999-02-12 2000-08-29 Nortran Pharmaceuticals Inc. Cycloalkyl amine compounds and uses thereof
US7053087B1 (en) * 1999-03-04 2006-05-30 Cardiome Pharma Corp. Aminocycloalkyl cinnamide compounds for arrhythmia and analgesics and anesthetics
US7507545B2 (en) * 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
CA2268590A1 (en) * 1999-04-12 2000-10-12 Nortran Pharmaceuticals Inc. Ion channel modulating compounds and uses thereof
US6150357A (en) * 1999-05-10 2000-11-21 Merck & Co., Inc. Potassium channel agonists
CA2404464C (en) * 2000-04-20 2008-03-11 F. Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and their use for the treatment of neurodegenerative disorders
CA2311483A1 (en) 2000-06-12 2001-12-12 Gregory N Beatch IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF
US6521619B2 (en) * 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
US6498170B2 (en) * 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
AU2003248647A1 (en) * 2002-06-14 2003-12-31 Johnson Matthey Pharmaceutical Materials, Inc. Stereoselective synthesis of 1,2-disubstituted cycloalkyls
GB2407093A (en) 2002-07-12 2005-04-20 Cardiome Inc Mutations of voltage-gated potassium channels
WO2004098525A2 (en) 2003-05-02 2004-11-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
KR101059379B1 (ko) * 2003-05-02 2011-08-26 카디오메 파마 코포레이션 아미노사이클로헥실 에테르 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
WO2005016242A2 (en) * 2003-06-04 2005-02-24 Cardiome Pharma Corp. Synthetic process for trans-aminocyclohexyl ether compounds
US7674820B2 (en) * 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US20070197632A1 (en) * 2003-10-31 2007-08-23 Cardiome Pharma Corp Aminocyclohexyl ether compounds and uses thereof
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof

Also Published As

Publication number Publication date
ATE325789T1 (de) 2006-06-15
EP1560812B1 (en) 2006-05-10
SG167670A1 (en) 2011-01-28
US20070099983A1 (en) 2007-05-03
RU2008104198A (ru) 2009-08-10
BRPI0318278B1 (pt) 2018-11-06
IL216579A (en) 2015-02-26
SG2010079697A (en) 2016-09-29
JP2006525227A (ja) 2006-11-09
BR122018009866B8 (pt) 2021-07-27
EP1560812A1 (en) 2005-08-10
JP4919661B2 (ja) 2012-04-18
US8163938B2 (en) 2012-04-24
DE60305200D1 (de) 2006-06-14
DK1560812T3 (da) 2006-09-04
US20070254945A1 (en) 2007-11-01
ES2264776T3 (es) 2007-01-16
AU2003287378A1 (en) 2004-11-26
DE60305200T2 (de) 2007-05-10
KR20060057531A (ko) 2006-05-26
NO334094B1 (no) 2013-12-09
CA2524323C (en) 2012-05-15
ATE529401T1 (de) 2011-11-15
EP1666459A3 (en) 2006-09-20
NZ543921A (en) 2008-11-28
PT1560812E (pt) 2006-09-29
RU2478617C2 (ru) 2013-04-10
IL171653A (en) 2013-06-27
HK1091814A1 (zh) 2007-01-26
EP1666459A2 (en) 2006-06-07
KR101059379B1 (ko) 2011-08-26
CY1105137T1 (el) 2010-03-03
EP1666459B1 (en) 2011-10-19
NO20055130D0 (no) 2005-11-02
AU2011201015B2 (en) 2012-02-02
SI1560812T1 (sl) 2006-10-31
AU2011201015A1 (en) 2011-03-31
US7767830B2 (en) 2010-08-03
BR0318278A (pt) 2006-05-23
PL227937B1 (pl) 2018-01-31
WO2004099137A1 (en) 2004-11-18
ES2375820T3 (es) 2012-03-06
JP2007077162A (ja) 2007-03-29
US20110004006A1 (en) 2011-01-06
PL378918A1 (pl) 2006-06-12
IL216579A0 (en) 2012-01-31
NO20055130L (no) 2005-12-01
EP2298735A1 (en) 2011-03-23
CA2524323A1 (en) 2004-11-18
AU2003287378B2 (en) 2010-12-16
BR122018009866B1 (pt) 2018-12-18

Similar Documents

Publication Publication Date Title
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
MY140539A (en) 1-amino 1h-imidazoquinolines
ES2158115T3 (es) Derivados de histidina y homohistidina como inhibidores de la farnesiltransferasa de proteinas.
TW200509983A (en) The dermal external agent for inhibiting or repairing the dermal damage due to drying
UA96115C2 (uk) Спосіб і композиція для лікування амілоїдогенних захворювань
WO2005118544A3 (en) Cycloalkyl substituted pyrimidinediamine compounds and their uses
AU2002251159A1 (en) Use of a phaeodactylum algae extract to promote the proteasome activity of skin cells
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
WO2005000248A3 (en) Compositions and methods for skin conditioning
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
BR0315437A (pt) Composição para o tratamento dos cabelos, usos da mesma e método para o tratamento dos cabelos
PL361134A1 (en) Pharmaceutical solutions of modafinil compounds
BRPI0510719A (pt) derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos
DE60008798D1 (de) Extrakt von undifferenzierten zellen einer pflanze der gattung leontopodium und ihn enthaltende zusammensetzungen
SE0003476D0 (sv) Compounds
TW200716088A (en) Formulations and methods for treating amyloidosis
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
BR0009194A (pt) Composição do resorcinol
DK1537132T3 (da) Salt af mortin-6-glucuronid
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
ES2187446T3 (es) Composicion para el tratamiento de la psoriasis.
IL182298A0 (en) 4-hydroxy tamoxifen gel formulations
DE50211461D1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 3A ANUIDADE.

B24D Patent annual fee: restoration after fee payment
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 3A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2607 DE 22/12/2020 POR TER SIDO INDEVIDA. UMA VEZ QUE A RESTAURACAO FOI CUMPRIDA EM 19/11/2020.

B25A Requested transfer of rights approved

Owner name: CORREVIO CANADA CORP. (CA)

B25A Requested transfer of rights approved

Owner name: CORREVIO INTERNATIONAL SARL (CH)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2496 DE 06/11/2018 QUANTO AO PRAZO DE VALIDADE. RETIFICACAO (PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO )